TNF Pharmaceuticals, Inc. (TNFA)

TNF Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	2023	2022	2021	2020	2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	4.66	5.44	5.52	6.42	2.95	5.76
Research & Development	6.47	7.87	9.07	6.75	2.47	3.63
Operating Expenses	13.4	16.36	15.28	28.2	8.3	9.39
Operating Income	-13.4	-16.36	-15.28	-28.2	-8.3	-9.39
Interest Expense	-	-	-	-0.61	-1.19	-0.25
Interest & Investment Income	0.29	0.46	0.08	0.01	0	-
Other Non Operating Income (Expenses)	-4.41	12.08	-	-	-	-
EBT Excluding Unusual Items	-17.51	-3.82	-15.2	-28.8	-9.49	-9.64
Gain (Loss) on Sale of Investments	0	0	-0	-0	-	-
Other Unusual Items	-0.18	-0.18	0	-1.09	-	-
Pretax Income	-17.69	-4	-15.2	-29.89	-9.49	-9.64
Net Income	-17.69	-4	-15.2	-29.89	-9.49	-9.64
Preferred Dividends & Other Adjustments	5.67	4.22	-	-	-	-
Net Income to Common	-23.35	-8.22	-15.2	-29.89	-9.49	-9.64
Shares Outstanding (Basic)	2	2	1	1	1	1
Shares Outstanding (Diluted)	2	2	1	1	1	1
Shares Change (YoY)	44.02%	19.18%	10.88%	24.23%	-25.94%	-
EPS (Basic)	-11.94	-5.33	-11.74	-25.61	-10.10	-7.60
EPS (Diluted)	-11.94	-5.33	-11.74	-25.61	-10.10	-7.60
Free Cash Flow	-9.67	-12.98	-12.27	-19.52	-4.66	-5.32
Free Cash Flow Per Share	-4.94	-8.42	-9.48	-16.72	-4.96	-4.19
EBITDA	-	-	-	-28.18	-8.28	-9.37
D&A For EBITDA	-	-	-	0.02	0.02	0.02
EBIT	-13.4	-16.36	-15.28	-28.2	-8.3	-9.39

Source: S&P Capital IQ. Standard template. Financial Sources.